The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cancer revoked: oncogenes as therapeutic targets
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Transcriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
Rhee, I., Bachman, K. E., Park, B. H., Jair, K.-W., Yen, R.-W. C., Schuebel, K. E., Cui, H., Feinberg, A. P., Lengauer, C., Kinzler, K. W., et al. (2002) · Nature · doi:10.1038/416552a · Cited by 1,039
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Self-citationEssential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade
Berman, D. M., Karhadkar, S. S., Hallahan, A. R., Pritchard, J. I., Eberhart, C. G., Watkins, D. N., Chen, J. K., Cooper, M. K., Taipale, J., Olson, J. M., et al. (2002) · Science · doi:10.1126/science.1073733 · Cited by 803
Di Croce, L., Raker, V. A., Corsaro, M., Fazi, F., Fanelli, M., Faretta, M., Fuks, F., Coco, F. L., Kouzarides, T., Nervi, C., et al. (2002) · Science · doi:10.1126/science.1065173 · Cited by 787
Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.
Kistner, A., Gossen, M., Zimmermann, F., Jerecic, J., Ullmer, C., Lübbert, H., & Bujard, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10933 · Cited by 778
A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G 0 Cells
Ogawa, H., Ishiguro, K.-I., Gaubatz, S., Livingston, D. M., & Nakatani, Y. (2002) · Science · doi:10.1126/science.1069861 · Cited by 768
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 644
Self-citationPelengaris, S., Khan, M., & Evan, G. I. (2002) · Cell · doi:10.1016/s0092-8674(02)00738-9 · Cited by 626
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582
Mutations and altered expression of p16INK4 in human cancer.
Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., & Beach, D. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11045 · Cited by 539
c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression
Baudino, T. A., McKay, C., Pendeville-Samain, H., Nilsson, J. A., Maclean, K. H., White, E. L., Davis, A. C., Ihle, J. N., & Cleveland, J. L. (2002) · Genes & Development · doi:10.1101/gad.1024602 · Cited by 525
Reversible Activation of c-Myc in Skin
Pelengaris, S., Littlewood, T., Khan, M., Elia, G., & Evan, G. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80350-0 · Cited by 468
Transient excess of MYC activity can elicit genomic instability and tumorigenesis
Felsher, D. W., & Bishop, J. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3940 · Cited by 419
Self-citationD'Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., Cox, J. D., Ha, S. I., Belka, G. K., Golant, A., et al. (2001) · Nature Medicine · doi:10.1038/84691 · Cited by 418
Reversibility of acute B-cell leukaemia induced by BCR–ABL1
Huettner, C. S., Zhang, P., Van Etten, R. A., & Tenen, D. G. (2000) · Nature Genetics · doi:10.1038/71691 · Cited by 413
Differentiation-Linked Leukemogenesis in Lymphocytes
Greaves, M. F. (1986) · Science · doi:10.1126/science.3535067 · Cited by 338
Role of DNA 5-Methylcytosine Transferase in Cell Transformation by fos
Bakin, A. V., & Curran, T. (1999) · Science · doi:10.1126/science.283.5400.387 · Cited by 238
Time-Sensitive Reversal of Hyperplasia in Transgenic Mice Expressing SV40 T Antigen
Ewald, D., Li, M., Efrat, S., Auer, G., Wall, R. J., Furth, P. A., & Hennighausen, L. (1996) · Science · doi:10.1126/science.273.5280.1384 · Cited by 236
Mutation and altered expression of p16^ in human cancer
Okamoto, A. (1994) · Proceedings of the National Academy of Sciences · Cited by 234
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis
Gunther, E. J., Moody, S. E., Belka, G. K., Hahn, K. T., Innocent, N., Dugan, K. D., Cardiff, R. D., & Chodosh, L. A. (2003) · Genes & Development · doi:10.1101/gad.1051603 · Cited by 214
Effect of oncogenic virus on muscle differentiation.
Holtzer, H., Biehl, J., Yeoh, G., Meganathan, R., & Kaji, A. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.10.4051 · Cited by 178
Cancer Epigenetics and Methylation
Esteller, M., Fraga, M. F., Paz, M. F., Campo, E., Colomer, D., Novo, F. J., Calasanz, M. J., Galm, O., Guo, M., Benitez, J. J., et al. (2002) · Science · doi:10.1126/science.297.5588.1807d · Cited by 135
Karlsson, A. E., Giuriato, S., Tang, F. L. M., Weier, J. F., Levan, G., & Felsher, D. W. (2003) · Blood · doi:10.1182/blood-2002-10-3091 · Cited by 117
Self-citationMolecular mechanisms of resistance to STI571 in chronic myeloid leukemia
Gorre, M. E., & Sawyers, C. L. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00007 · Cited by 113
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia
Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00080-6 · Cited by 110
Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics
Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00022-3 · Cited by 52
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Sanz, M. Á., Martín, G., & Díaz-Mediavilla, J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802053380613 · Cited by 20
Cited by
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Multifunctional sonosensitizers in sonodynamic cancer therapy
Son, S., Kim, J. H., Wang, X., Zhang, C., Yoon, S. A., Shin, J., Sharma, A., Lee, M. H., Cheng, L., Wu, J., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00648f · Cited by 1,150
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874
Self-citationMYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Gabay, M., Li, Y., & Felsher, D. W. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014241 · Cited by 818
Self-citation
Metadata
- Authors
- Felsher, D. W.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 375-379
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1573646548
- Cited by
- 556
- References
- 37
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.